BREAST CANCER

Camizestrant plus CDK4/6 inhibition improved progression-free survival when given to patients with ESR1-mutant ER+/HER2– breast cancer in the SERENA-6 trial.

Erin Cobain, MD, discusses findings from a study exploring the differences in diagnosis and treatment of high-risk breast cancer in Black and White patients.

Sara M. Tolaney, MD, MPH, shares new data from the ASCENT-04 trial of sacituzumab govitecan and pembrolizumab in triple-negative breast cancer.

Vepdegestrant significantly improved progression-free survival vs fulvestrant in pretreated ESR1-mutant, ER-positiver, HER2-negative advanced breast cancer.

Sacituzumab govitecan & pembrolizumab significantly improved PFS in PD-L1+ advanced TNBC vs. chemo/pembrolizumab in the ASCENT-04 study.

Sara M. Tolaney, MD, MPH, highlights a transformative year for breast cancer research at this year’s ASCO Annual Meeting.

In ASCENT-03, sacituzumab govitecan significantly extended progression-free survival in metastatic triple-negative breast cancer not eligible for PD-(L)1 inhibitors.

INAVO120 trial shows inavolisib, palbociclib, and fulvestrant significantly improved overall survival in PIK3CA-mutant advanced breast cancer.

During a Community Case Forum event, Antoinette R. Tan, MD, MHS, discussed the DESTINY-Breast04 and DESTINY-Breast06 trials in HER2-low and -ultralow breast cancer.

Samuraciclib improved progression-free survival in HR+ advanced breast cancer patients without TP53 mutations or liver metastases.

Findings from the TROPION-Lung04 study were presented at the ESMO Targeted Anticancer Therapies Congress 2025 in March.

Adding pertuzumab to standard of care improved survival by 17% in patients with early-stage HER2-positive breast cancer.

During a live event, Gregory Vidal, MD, PhD, discussed the adjuvant trials of abemaciclib and ribociclib and how their different dosing approaches and safety profiles can affect their usage in breast cancer.

T-DXd monotherapy and T-DXd plus pertuzumab continue to show robust efficacy in HER2-positive metastatic breast cancer.

During a live event, Megan Kruse, MD, discussed sacituzumab govitecan's benefit, dosing, toxicity, and an ongoing earlier-line trial in metastatic breast cancer.

A phase 1b/2 trial in triple-negative breast cancer will assess LP-184 alone and with a PARP inhibitor in advanced cases.

ASCENT-04 data showed sacituzumab govitecan plus pembrolizumab improved progression-free survival in PD-L1+ metastatic triple-negative breast cancer.

Phase 2 data suggest a survival benefit with Bria-IMT and retifanlimab in heavily pretreated HR-positive metastatic breast cancer, outperforming historical controls.

During a live event, Megan Kruse, MD, discussed NCCN guidelines and key therapies for patients with HR-positive metastatic breast cancer.

During a a live event, Virginia Kaklamani, MD, DSc, and participants discussed their experiences using a PI3K/AKT inhibitor in patients with metastatic breast cancer.

Fengting Yan, MD, PhD, discusses how her clinical practice is informed by data and guidelines available on testing in breast cancer.

The FDA has granted 501(k) clearance to ZEISS INTRABEAM 700, a robotic-assisted platform designed to enhance intraoperative radiation therapy.

Seth Wander, MD, PhD, discusses the extended survival with elacestrant in a real-world, which was longer than the randomized phase 3 trial data.

Vepdegestrant extended PFS vs fulvestrant in patients with ESR1m+, ER+/HER2– breast cancer who progressed on CDK 4/6 inhibitors and endocrine therapy.

Seth Wander, MD, PhD, discusses the tolerability of selective estrogen receptor degraders and next-generation anti-estrogen agents in breast cancer.